ORTIN GLOBAL growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−70.6%−83.8%−64.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−17.2%+86.5%−1,355.4%
−15.7%+86.8%−2,600.2%
+12.5%+89.5%−11,919.4%
+12.5%+89.5%−12,262.5%
+22.9%−42.6%−68.9%
−37.4%−30.0%−74.0%
−36.4%+88.8%−1,585.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ORTINGLOBE₹13.13

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹10.7 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-64.9-83.8-70.6—
EBITDA Growth—-1,355.4+86.5-17.2—
EBIT Growth—-2,600.2+86.8-15.7—
Net Income Growth—-11,919.4+89.5+12.5—
EPS Growth—-12,262.5+89.5+12.5—
Total Assets Growth—-68.9-42.6+22.9—
Total Equity Growth—-74.0-30.0-37.4—
Cash from Operations Growth—-1,585.7+88.8-36.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.